General Newsroom Hero 1920x480 (4:1)
Our Work

Latham & Watkins Advises Frontier Medicines in its Global Partnership with AbbVie

December 4, 2020
A life sciences team advises the precision medicine company in the transaction which will focus on discovering and developing novel therapies and E3 degraders against difficult-to-drug targets.

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Frontier Medicines, Corp., a precision medicine company drugging challenging protein targets to develop breakthrough medicines that change the course of human diseases, have announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative small molecule therapeutics against high-interest, difficult-to-drug protein targets.

Latham & Watkins LLP represents Frontier Medicines, Corp. in the partnership. Bay Area partner Judith Hasko and associate Peggy Ni advised on the strategic collaboration and Bay Area partner Kathleen Wells advised on corporate aspects of the transaction. Advice was also provided on tax matters by Bay Area partner Grace Lee, with Washington, D.C. associate Amy Feinberg; and on data privacy matters by London associates Frances Stocks Allen and Oliver Mobasser. 


    Related Capabilities